Patents Assigned to Shire LLC
  • Publication number: 20120141580
    Abstract: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or lanthanum hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The capsules of the present invention dissolve at a similar rate before and after storage. The oral pharmaceutical capsules of the present invention can be administered to treat a patient at risk for or suffering from hyperphosphatemia, at risk for or suffering from chronic kidney disease (CKD), at risk for or suffering from soft tissue calcification associated with CKD, or at risk for or suffering from secondary hyperparathyroidism.
    Type: Application
    Filed: December 1, 2010
    Publication date: June 7, 2012
    Applicant: Shire, LLC
    Inventor: Roger Withington
  • Publication number: 20120141581
    Abstract: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.
    Type: Application
    Filed: November 30, 2011
    Publication date: June 7, 2012
    Applicant: Shire, LLC
    Inventors: Roger WITHINGTON, David Pierce
  • Publication number: 20120115950
    Abstract: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Type: Application
    Filed: December 28, 2011
    Publication date: May 10, 2012
    Applicant: SHIRE LLC
    Inventors: Travis Mickle, Suma Krishnan, Barney Bishop, Christopher Lauderback, James Scott Moncrief, Robert Oberlender, Thomas Piccariello, Bernhard J. Paul, Christopher A. Verbicky
  • Publication number: 20120065152
    Abstract: Prodrugs of guanfacine, pharmaceutical compositions containing such prodrugs and a method for providing therapeutic benefit in the treatment of ADHD/ODD (attention deficient hyperactivity disorder and oppositional defiance disorder) with guanfacine prodrugs are provided herein. Additionally, methods for improving the pharmacokinetics of guanfacine or minimizing or avoiding the adverse gastrointestinal side effects associated with guanfacine administration are provided herein.
    Type: Application
    Filed: September 14, 2011
    Publication date: March 15, 2012
    Applicant: SHIRE LLC
    Inventors: Rhys Whomsley, Bernard T. Golding, Robert G. Tyson
  • Patent number: 8133881
    Abstract: The invention provides a “street-safe” version of a controlled substance that permits the therapeutically beneficial effects of the substance while reducing or eliminating the euphoric effects that lead to substance abuse. The invention provides pharmaceutical compositions comprising a controlled substance and a carbohydrate covalently bound to said controlled substance in a manner that renders said controlled substance pharmacologically inactive or substantially diminishes its activity and methods of using the same.
    Type: Grant
    Filed: July 13, 2005
    Date of Patent: March 13, 2012
    Assignee: Shire LLC
    Inventors: Travis Mickle, Thomas Piccariello, James Scott Moncrief, Nancy Johnston Boerth, Barney Bishop
  • Patent number: 8106016
    Abstract: The invention relates to pharmaceutical compounds and compositions comprised of a chemical moiety attached to an opioid such as oxycodone in a manner that substantially decreases the potential of the opioid to cause overdose. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent. Further the compounds and compositions of the invention are useful in preventing addiction and susceptibility to addiction.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: January 31, 2012
    Assignee: Shire LLC
    Inventors: James Scott Moncrief, Suma Krishnan, Travis Mickle, Christopher Lauderback, Sanjib Bera, Sven Guenther, Wendy Hirschelman
  • Publication number: 20110263850
    Abstract: The present invention relates to a novel process for producing quinazoline compounds which are useful in therapy. More specifically, the compounds produced by the process of the invention are useful in the treatment of a number of cardiovascular diseases. The process of the invention provides 6,7-dichloro-1,5- dihydroimidazo [2,1 -b] quinazolin 2 (3H)-one, more commonly known as anagrelide and its analogues in a clean and efficient manner.
    Type: Application
    Filed: November 30, 2009
    Publication date: October 27, 2011
    Applicant: SHIRE LLC
    Inventor: Bernard Golding
  • Publication number: 20110152298
    Abstract: This invention relates to the discovery of substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the general formula shown below where the substituents have the meanings defined in claim (I) and which have utility as platelet lowering agents in humans. The compounds of the present invention function by inhibiting megakaryocytopoeisis and hence the formation of blood platelets.
    Type: Application
    Filed: May 13, 2009
    Publication date: June 23, 2011
    Applicant: SHIRE LLC
    Inventors: Bernard T. Golding, Richard Franklin, Angus Macleod, Peter Cicala
  • Publication number: 20110130405
    Abstract: This invention relates to the discovery of 3-and 5-substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the general formula (I) shown below wherein the meanings of the substituents are defined in claim 1 and which have utility as platelet lowering agents in humans. The compounds of the present invention function by inhibiting megakaryocytopoeisis and hence the formation of blood platelets.
    Type: Application
    Filed: May 13, 2009
    Publication date: June 2, 2011
    Applicant: Shire LLC
    Inventors: Bernard Golding, Richard Franklin, Kim Hirst
  • Publication number: 20110130413
    Abstract: This invention relates to the discovery of prodrugs of substituted analogues of the selective platelet lowering agent anagrelide which have reduced potential for cardiovascular side-effects and which should therefore lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to prodrugs of certain imidazoquinazoline derivatives which have the general formula (I) shown below wherein the substituents have the meanings defined in claim 1 and which have utility as platelet lowering agents in humans. The compounds of the present invention function by inhibiting the formation of blood platelets.
    Type: Application
    Filed: May 13, 2009
    Publication date: June 2, 2011
    Applicant: Shire LLC
    Inventors: Bernard Golding, Peter Cicala, Richard Franklin, Angus Macleod
  • Publication number: 20110098278
    Abstract: Prodrugs of galantamine or its 3-hydroxy metabolite with amino acids or short peptides, pharmaceutical compositions containing such prodrugs and methods for treating a memory or cognition disorder with the galantamine prodrugs are provided herein. Prodrugs having side chains of valine, phenylalanine, tyrosine or para amino benzoic acid and mono-, di- and tripeptides thereof are preferred. Additionally, methods for avoiding or minimizing the adverse gastrointestinal side effects associated with galantamine administration, as well as improving the pharmacokinetics of galantamine are provided herein.
    Type: Application
    Filed: July 23, 2010
    Publication date: April 28, 2011
    Applicant: Shire LLC
    Inventors: Richard Franklin, Bernard T. Golding, Robert G. Tyson
  • Publication number: 20110071172
    Abstract: This invention relates to the discovery of substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the general formula shown below wherein the substituents have the meanings defined in claim (I): and which have utility as platelet lowering agents in humans. The compounds of the present invention function by inhibiting megakaryocytopoeisis and hence the formation of blood platelets.
    Type: Application
    Filed: May 13, 2009
    Publication date: March 24, 2011
    Applicant: Shire LLC
    Inventors: Bernard Golding, Richard Franklin
  • Publication number: 20110071171
    Abstract: This invention relates to the discovery of substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the general formula shown below wherein the substituents have the meanings defined in claim 1: and which have utility as platelet lowering agents in humans. The compounds of the present invention function by inhibiting megakaryocytopoeisis and hence the formation of blood platelets.
    Type: Application
    Filed: May 13, 2009
    Publication date: March 24, 2011
    Applicant: Shire LLC
    Inventors: Bernard Golding, Richard Franklin
  • Patent number: 7910597
    Abstract: This invention relates to the discovery of 3- and 5-substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have utility as platelet lowering agents in humans. The compounds of the present invention function by inhibiting megakaryocytopoeisis and hence the formation of blood platelets.
    Type: Grant
    Filed: November 28, 2007
    Date of Patent: March 22, 2011
    Assignee: Shire LLC
    Inventors: Richard Franklin, Bernard T. Golding
  • Publication number: 20110065735
    Abstract: This invention relates to the discovery of substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the general formula shown below wherein the substituents have the meanings defined in claim 1: and which have utility as platelet lowering agents in humans. The compounds of the present invention function by inhibiting megakaryocytopoeisis and hence the formation of blood platelets.
    Type: Application
    Filed: May 13, 2009
    Publication date: March 17, 2011
    Applicant: Shire LLC
    Inventors: Bernard Golding, Richard Franklin, Peter Cicala
  • Publication number: 20110065714
    Abstract: This invention relates to the discovery of 3-and 5-substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the general formula shown below wherein the substituents have the meanings defined in claim 1: and which have utility as platelet lowering agents in humans. The compounds of the present invention function by inhibiting megakaryocytopoeisis and hence the formation of blood platelets.
    Type: Application
    Filed: May 13, 2009
    Publication date: March 17, 2011
    Applicant: Shire LLC
    Inventors: Bernard Golding, Peter Cicala, Richard Franklin, Kim Hirst
  • Publication number: 20110065796
    Abstract: Prodrugs of guanfacine with amino acids or short peptides, pharmaceutical compositions containing such prodrugs and a method for providing therapeutic benefit in the treatment of ADHD/ODD (attention deficient hyperactivity disorder and oppositional defiance disorder) with guanfacine prodrugs are provided herein. Additionally, methods for minimizing or avoiding the adverse gastrointestinal side effects associated with guanfacine administration, as well as improving the pharmacokinetics of guanfacine are provided herein.
    Type: Application
    Filed: September 15, 2010
    Publication date: March 17, 2011
    Applicant: SHIRE LLC
    Inventors: Rhys Whomsley, Richard Franklin, Bernard T. Golding, Robert G. Tyson
  • Publication number: 20110046226
    Abstract: The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.
    Type: Application
    Filed: September 13, 2010
    Publication date: February 24, 2011
    Applicant: SHIRE LLC
    Inventors: TRAVIS MICKLE, SUMA KRISHNAN, JAMES SCOTT MONCRIEF, CHRISTOPHER LAUDERBACK
  • Publication number: 20110040072
    Abstract: The invention relates to pharmaceutical compounds and compositions comprised of a chemical moiety attached to oxycodone in a manner that substantially decreases the potential for overdose. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of oxycodone and may also provide sustained release characteristics and/or reduced side-effects. Further the compounds and compositions of the invention are useful in preventing addiction and susceptibility to addiction of oxycodone.
    Type: Application
    Filed: March 11, 2010
    Publication date: February 17, 2011
    Applicant: SHIRE LLC
    Inventors: Travis Mickle, Suma Krishnan, James Scott Moncrief, Christopher Lauderback, Sanjib Bera
  • Publication number: 20110009669
    Abstract: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Type: Application
    Filed: February 5, 2010
    Publication date: January 13, 2011
    Applicant: SHIRE LLC
    Inventors: Travis Mickle, Suma Krishnan, Barney Bishop, Christopher Lauderback, James Scott Moncrief, Robert Oberlender, Thomas Piccariello, Bernhard J. Paul, Christopher A. Verbicky